Active Surveillance for Cancer of the Prostate (ASCaP)
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 30 - 85 |
| Updated: | 3/1/2019 |
| Start Date: | June 4, 2009 |
| End Date: | December 2021 |
| Contact: | Malu Macairan |
| Email: | mmacairan@mednet.ucla.edu |
| Phone: | (310) 794-3566 |
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.
Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with
low-risk, localized lesions, with curative treatment of those whose tumors show substantial
progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative
treatment of men with progressive prostate cancer.
low-risk, localized lesions, with curative treatment of those whose tumors show substantial
progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative
treatment of men with progressive prostate cancer.
This protocol is not designed as a formal clinical trial, but rather an observational
protocol; no treatments and no randomization are included. Longitudinally, specimens and
clinical data will be collected to provide information on the following:
- Imaging studies of the prostate
- Rates of curative intervention
- Measures of tumor recurrence/progression
- Disease specific survival
- Overall survival
- Clinical data to track Quality of Life
protocol; no treatments and no randomization are included. Longitudinally, specimens and
clinical data will be collected to provide information on the following:
- Imaging studies of the prostate
- Rates of curative intervention
- Measures of tumor recurrence/progression
- Disease specific survival
- Overall survival
- Clinical data to track Quality of Life
Inclusion Criteria:
1. Histologically confirmed adenocarcinoma of the prostate.
2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
3. No previous treatment for prostate cancer (including hormonal therapy, radiation
therapy, surgery, or chemotherapy).
4. Patient has elected Active Surveillance as preferred management plan for prostate
cancer.
5. Patient consent has been obtained according to local Institutional Review Board .
6. Patient is accessible and compliant for follow-up.
Exclusion Criteria:
1. Unwillingness or inability to undergo serial prostate biopsy.
2. Overall life expectancy less than 2 years
3. Advanced prostate cancer
We found this trial at
1
site
Los Angeles, California 90095
310-825-4321
Principal Investigator: Leonard S Marks, M.D.
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
Click here to add this to my saved trials
